265 related articles for article (PubMed ID: 19369827)
1. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
Beauparlant P; Bédard D; Bernier C; Chan H; Gilbert K; Goulet D; Gratton MO; Lavoie M; Roulston A; Turcotte E; Watson M
Anticancer Drugs; 2009 Jun; 20(5):346-54. PubMed ID: 19369827
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma.
Kato H; Ito E; Shi W; Alajez NM; Yue S; Lee C; Chan N; Bhogal N; Coackley CL; Vines D; Green D; Waldron J; Gullane P; Bristow R; Liu FF
Clin Cancer Res; 2010 Feb; 16(3):898-911. PubMed ID: 20103674
[TBL] [Abstract][Full Text] [Related]
3. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.
Watson M; Roulston A; Bélec L; Billot X; Marcellus R; Bédard D; Bernier C; Branchaud S; Chan H; Dairi K; Gilbert K; Goulet D; Gratton MO; Isakau H; Jang A; Khadir A; Koch E; Lavoie M; Lawless M; Nguyen M; Paquette D; Turcotte E; Berger A; Mitchell M; Shore GC; Beauparlant P
Mol Cell Biol; 2009 Nov; 29(21):5872-88. PubMed ID: 19703994
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
5. Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Chan M; Gravel M; Bramoullé A; Bridon G; Avizonis D; Shore GC; Roulston A
Cancer Res; 2014 Nov; 74(21):5948-54. PubMed ID: 25145669
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
7. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
8. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.
Hjarnaa PJ; Jonsson E; Latini S; Dhar S; Larsson R; Bramm E; Skov T; Binderup L
Cancer Res; 1999 Nov; 59(22):5751-7. PubMed ID: 10582695
[TBL] [Abstract][Full Text] [Related]
9. NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors.
Elf AK; Bernhardt P; Hofving T; Arvidsson Y; Forssell-Aronsson E; Wängberg B; Nilsson O; Johanson V
J Nucl Med; 2017 Feb; 58(2):288-292. PubMed ID: 27688470
[TBL] [Abstract][Full Text] [Related]
10. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice.
Saif MW; von Borstel R
Cancer Chemother Pharmacol; 2006 Jul; 58(1):136-42. PubMed ID: 16187114
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
12. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
13. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA
Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987
[TBL] [Abstract][Full Text] [Related]
14. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
Stover TC; Sharma A; Robertson GP; Kester M
Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route.
Chou TC; Dong H; Zhang X; Tong WP; Danishefsky SJ
Cancer Res; 2005 Oct; 65(20):9445-54. PubMed ID: 16230408
[TBL] [Abstract][Full Text] [Related]
17. Anticancer agent CHS-828 inhibits cellular synthesis of NAD.
Olesen UH; Christensen MK; Björkling F; Jäättelä M; Jensen PB; Sehested M; Nielsen SJ
Biochem Biophys Res Commun; 2008 Mar; 367(4):799-804. PubMed ID: 18201551
[TBL] [Abstract][Full Text] [Related]
18. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
[TBL] [Abstract][Full Text] [Related]
19. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
Friedlos F; Davies L; Scanlon I; Ogilvie LM; Martin J; Stribbling SM; Spooner RA; Niculescu-Duvaz I; Marais R; Springer CJ
Cancer Res; 2002 Mar; 62(6):1724-9. PubMed ID: 11912146
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner.
Cerna D; Li H; Flaherty S; Takebe N; Coleman CN; Yoo SS
J Biol Chem; 2012 Jun; 287(26):22408-17. PubMed ID: 22570471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
